Post Transplant Lymphoproliferative Disorder

AbstractPosttransplant lymphoproliferative disorder is an extremely fatal complication arising in transplant recipients as a side effect of immunosuppression. PTLDs are seen after both solid organ and hematopoietic stem cell transplants though the incidence is much higher in the former. Primary Epstein –Barr virus (EBV) infection or reactivation due to a state of immune dysregulation along with intensity of immunosuppression used are of paramount importance in pathogenesis of PTLD. EBV associated PTLDs occur early in the post transplant period whereas late onset lymphomas are usually EBV negativ e. The uncontrolled B cell proliferation can create a spectrum of histological patterns from nondestructive lesions to destructive polymorphic or more aggressive monomorphic PTLDs. Early detection of seropositivity by serial monitoring in the recipient can prevent PTLD development by starting pre-em ptive therapy. The mainstay treatment in established cases remains reduction of immunosuppression. Chemotherapeutic and immunomodulatory agents are added sequentially based on the type of PTLD and based on its response to initial therapy. Despite various treatment options available, the morbidity re mains high and achieving state of disease remission without causing graft rejection can be quite challenging. Hence, a better understanding in pathobiology of EBV+ versus EBV− PTLDS may help prevent lymphomagenesis in transplant recipients.
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research

Related Links:

This study included 18 buffy coats collected from volunteer blood donors admitted to the blood transfusion service of IRCCS Bambino Gesù Pediatric Hospital after obtaining informed consent. The Ethical Committee of IRCCS Bambino Gesù Pediatric Hospital approved the study (825/2014) and conducted in accordance with the ethical principles stated in the Declaration of Helsinki. Cells Lines and Cell Culture NK-92 (malignant non-Hodgkin's lymphoma), K562 (chronic myelogenous leukemia, CD19−), Jurkat (acute T cell leukemia, CD19−) Karpas 299 (Human Non-Hodgkin's Ki-positive Large Cell ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
AbstractLymphomas constitute a vast and heterogenous group of predominantly solid haematopoietic malignancies. Immunohistochemistry has always played a pivotal role in the diagnosis of lymphomas. Many new prognostic immunohistochemical markers have also come up and are being increasingly employed. The unraveling of molecular pathways in the study of lymphomas has opened the possibility of various new prognostic markers. Staging of lymphomas relies a lot on imaging. With the increasing use of positron emission tomography/computerized tomography scan for staging, many studies have shown that it has a high sensitivity for det...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Better treatment options, dietary conditions and (perhaps) less stress could make the life of the rich also healthier. However, when it comes to longevity and aging, do they really have better chances? Can the upper 0.1 percent secure their health for long decades or even reverse the process of growing old? Could society somehow also benefit from the quest of the richest for longevity? Are health and longevity on the shopping list? You can have an awful lot of things with money. For a starter, you can buy ice cream or Nutella, which are synonymous to self-love, so the Beatles was only partly right in singing that you can&r...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Bioethics Cyborgization Future of Medicine Medical Professionals Patients Policy Makers age aging aging research blood eternal life genetics immortality Innovation life sciences longevity silicon valley stem cell Source Type: blogs
Background:Somatic driver mutations in hematopoietic cells may lead to clonal hematopoiesis of indeterminate potential (CHIP). In patients with lymphoma CHIP has been associated with increased risk of therapy-related myeloid neoplasms (tMN) and inferior survival after autologous stem cell transplantation as demonstrated in a large single center study and in a case-control study (Gibson CJ et al., JCO 2017 and Berger G et al., Blood 2018). Here, we investigated the clinical impact of clonal hematopoiesis in a nation-wide population-based cohort of Danish lymphoma patients undergoing autologous transplant with prospective da...
Source: Blood - Category: Hematology Authors: Tags: 731. Clinical Autologous Transplantation: Results: Autologous Transplantation: Clonal Hematopoiesis, Microbiota, AML, NHL, and Autoimmune Diseases Source Type: research
Conclusions: To our knowledge this is the largest study of intravesicular cidofovir for BKV HC reported to date; 77% of patients with BVK HC achieved clinical improvement of symptoms with minimal side effects. Clinical trials of intravesicular cidofovir could provide further evidence for adding intravesicular cidofovir as a standard tool for the treatment of BKV HC.DisclosuresBadros: Celgene: Consultancy, Research Funding; Karyopharm: Research Funding; GSK: Research Funding.
Source: Blood - Category: Hematology Authors: Tags: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities: Poster I Source Type: research
When Nichelle Obar learned she was pregnant with her second child last year, she never expected that her pregnancy, or her baby, would make history. But when the 40-year-old food-and-beverage coordinator from Hawaii and her fiancé Christopher Constantino went to their 18-week ultrasound, they learned something was wrong. The heart was larger than it should have been, and there was evidence that fluid was starting to build up around the organ as well. Both were signs that the fetus was working extra hard to pump blood to its fast-growing body and that its heart was starting to fail. Obar’s doctor knew what coul...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized medicine Source Type: news
AbstractUse of growth factor after high-dose chemotherapy (HDC) and autologous peripheral blood stem cell (PBSC) support is current standard in reducing days of neutropenia. This retrospective study aims to compare the efficacy of two standard growth factors, pegfilgrastim (PEG) and filgrastim (FIL) after HDC. We collected data on 195 consecutive adult patients who received an autotransplant (myeloma, lymphoma and others) between January 2004 and December 2014 at two tertiary care centres. The primary end point was the duration of neutropenia in terms of days to reach an ANC  >  0.5 × 1...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
CONCLUSION: Results from this population-based overview of blood use in hematologic malignancies showed high variability depending on diagnosis and age. PMID: 29250794 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
This study enrolled 30 adult patients with m-PTLD after kidney-transplantation (KT, n  = 17) and hematopoietic stem cell transplantation (HSCT, n = 13) from January 1998 to December 2014. The incidence rates of m-PTLD were 0.74 and 3.63% in the KT and HSCT groups, respectively. M-PTLD patients in the HSCT group were younger and showed earlier onset, with EBV-encoded small RNAs (E BER) more frequently identified. Diffuse large B cell lymphoma (DLBCL) was the main pathological type, and the digestive system was the most extranodal involvement site in m-PTLD after KT and HSCT. Among the 28 patients with DL...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
More News: Blood Transusion | Hematology | India Health | Lymphoma | Stem Cell Therapy | Stem Cells | Transplants